Nektar Therapeutics Operating Lease Cost
Nektar Therapeutics (NKTR) reported Operating Lease Cost of $7.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-13
- Nektar Therapeutics operating lease, cost for the quarter ending 2019-12-31 was $4.67M, a 101.08% increase year-over-year.
- Nektar Therapeutics operating lease, cost for the quarter ending 2019-09-30 was $4.12M, a 113.60% increase year-over-year.
- Nektar Therapeutics operating lease, cost for the quarter ending 2019-06-30 was $2.96M, a 56.79% increase year-over-year.
- Nektar Therapeutics operating lease, cost for the quarter ending 2019-03-31 was $2.96M, a 60.88% increase year-over-year.
- Nektar Therapeutics operating lease, cost for fiscal 2025 was $7.16M, a 17.98% decline from fiscal 2024.
- Nektar Therapeutics operating lease, cost for fiscal 2024 was $8.72M, a 28.00% decline from fiscal 2023.
- Nektar Therapeutics operating lease, cost for fiscal 2023 was $12.12M, a 28.97% decline from fiscal 2022.
- Nektar Therapeutics operating lease, cost for fiscal 2022 was $17.06M, a 10.94% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.16M 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $8.72M 10-K · filed 2026-03-13 | |||
| 2023-12-31 | $12.12M 10-K · filed 2025-03-14 | |||
| 2022-12-31 | $17.06M 10-K · filed 2024-03-05 | |||
| 2021-12-31 | $19.15M 10-K · filed 2024-03-05 | |||
| 2020-12-31 | $18.98M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $8.78M derived: sum of 2 quarters · filed 2022-03-01 | $11.74M derived: sum of 3 quarters · filed 2022-03-01 | $14.70M 10-K · filed 2022-03-01 |
| 2019-09-30 | $4.12M 10-Q · filed 2019-11-07 | $7.07M derived: sum of 2 quarters · filed 2019-11-07 | $10.03M 10-Q · filed 2019-11-07 | $12.35M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.96M 10-Q · filed 2019-08-09 | $5.91M 10-Q · filed 2019-08-09 | $8.23M derived: sum of 3 quarters · filed 2021-02-26 | $10.16M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $2.96M 10-Q · filed 2019-05-09 | $5.28M derived: sum of 2 quarters · filed 2021-02-26 | $7.21M derived: sum of 3 quarters · filed 2021-02-26 | $9.09M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $4.25M derived: sum of 2 quarters · filed 2021-02-26 | $6.13M derived: sum of 3 quarters · filed 2021-02-26 | $7.97M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.93M 10-Q · filed 2019-11-07 | $3.81M derived: sum of 2 quarters · filed 2019-11-07 | $5.65M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $1.89M 10-Q · filed 2019-08-09 | $3.72M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.84M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $4.51M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |